Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2019
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing RegimensR R Kempker, L Mikiashvili, Y Zhao, et al.
The American Journal of Medicine|April 27, 1987
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infectionsD E Nix, M F Sands, C A Peloquin, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?G L Drusano, Brandon Duncanson, C A Scanga, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
Antimicrobial Agents and Chemotherapy|November 17, 2020
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy RegimensG L Drusano, Sarah Kim, Mohammed Almoslem, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitusY Alkabab, J Warkentin, J Cummins, et al.
Tuberculosis (Edinburgh, Scotland)|November 19, 2003
Direct lung delivery of para-aminosalicylic acid by aerosol particlesN Tsapis, D Bennett, K O'Driscoll, et al.
Arthritis and Rheumatism|November 9, 2012
Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritisT L Glover, B R Goodin, A L Horgas, et al.
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Antimicrobial Agents and Chemotherapy|June 1, 2017
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for TuberculosisC A Peloquin, G E Velásquez, L Lecca, et al.
Pageof 8